Abstract
Background Treatment for all recommendations has allowed access to antiretroviral (ARV) treatment to an increasing number of patients. This minimizes transmission of infection but can potentiate the risk for development of transmitted drug resistance (TDR) and acquired drug resistance (ADR).
Objective To study the trends of TDR and ADR in patients followed in Portuguese hospitals between 2001 and 2017.
Method 11911 patients of the Portuguese REGA database were included. TDR was defined as the presence of one or more surveillance drug resistance mutations according to the WHO surveillance list. Phenotypic resistance to ARV was evaluated with Standford HIVdb v7.0. Patterns of TDR, ADR and prevalence of mutations over time were analysed with logistic regression.
Results The prevalence of TDR increased from 7.9% in 2003 to 13.1% in 2017 (pfor-trend<0.001). This was due to a significant increase of both resistance mutations to nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleotide reverse transcriptase inhibitors (NNRTIs) from 5.6% to 6.7% (pfor-trend=0.002) and 2.9% to 8.9% (pfor-trend<0.001), respectively. TDR to Protease Inhibitors decreased from 4.0% in 2003 to 2.2 in 2017 (pfor-trend =0.985). Paradoxically, the prevalence of ADR declined from 86.6% in 2001 to 51.0% in 2017 (pfor-trend<0.001) caused by a declining drug resistance to all ARV classes (pfor-trend<0.001).
Conclusions While ADR is declining since 2001, TDR has been increasing, reaching a value of 13.1% by the end of 2017. It is urgent to develop public health programs to monitor levels and patterns of TDR in newly diagnosed patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by European Funds through grant ‘Bio-Molecular and Epidemiological Surveillance of HIV Transmitted Drug Resistance, Hepatitis Co-Infections and Ongoing Transmission Patterns in Europe - BEST HOPE - (project funded through HIVERA: Harmonizing Integrating Vitalizing European Research on HIV/Aids, grant 249697); by FCT for funds to GHTM-UID/Multi/04413/2013; by the MigrantHIV project (financed by FCT: PTDC/DTP-EPI/7066/2014); by Gilead Génese HIVLatePresenters and by Characterization of drug-resistance TB and HIV, and associated socio-behavioral factors among migrants in Lisbon, Portugal project financed by GHTM-UID/Multi/04413/2013
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Authors’ e-mail addresses MP- martapingarilho{at}ihmt.unl.pt
VP- victor.pimentel{at}ihmt.unl.pt
ID- ifmadeira{at}chlo.min-saude.pt
SF- smfernandes{at}chlo.min-saude.pt
MM- a21000919{at}ihmt.unl.pt
AP- andreapinedap{at}gmail.com
PL- pieter.libin{at}vub.ac.be
KT- kristof.theys{at}kuleuven.be
MRM- mrfom{at}ihmt.unl.pt
AV- annemie.vandamme{at}kuleuven.be
RC- ricardojorge.camacho{at}kuleuven.be
PG- pcrsilva{at}chlo.min-saude.pt
AA- ana.abecasis{at}ihmt.unl.pt
↵& Membership of the Portuguese HIV-1 Resistance Study Group is provided in the Acknowledgements
Data Availability
Data are available upon request